InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2022-03-15 00:00:00 ET · period of report 2022-03-14 · accession 0001883850-22-000020 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2022-03-15 2022-01-04 REGN VAGELOS P ROY Dir G - Gift $0.00 -338 141.3K -0.2% $0
D 2022-03-15 2022-03-14 REGN VAGELOS P ROY Dir M - OptEx $179.13 +75.0K 393.7K +24% +$13.43M
D 2022-03-15 2022-03-14 REGN VAGELOS P ROY Dir F - Tax $655.29 -48.1K 345.6K -12% -$31.52M
D 2022-03-15 2022-03-14 REGN VAGELOS P ROY Dir M - OptEx $0.00 -75.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-04 G D 338 $0.00 141,292 I — —
2 Common Common Stock 2022-03-14 M A 75,000 $179.13 393,669 D by CLAT — —
3 Common Common Stock 2022-03-14 F D 48,103 $655.29 345,566 D — —
4 Derivative Non-Qualified Stock Option (right to buy) 2022-03-14 M D 75,000 $0.00 0 D $179.13 · — to 2022-12-14 75,000 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.